CoChat
Sign Up
Cited by 396

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

The microRNA miR-23b suppresses IL-17-associated autoimmune inflammation by targeting TAB2, TAB3 and IKK-α

Zhu, Shu, Pan, Wen, Song, Xinyang, Liu, Yan, Shao, Xinrui, Tang, Yuanjia, Liang, Dong, He, Dongyi, Wang, Honglin, Liu, Wenjun, Shi, Yufang, Harley, John B, Shen, Nan, Qian, Youcun·2012·Nature Medicine
DOI 10.1038/nm.2815
Open this paper in CoChat — free account

Abstract

Inflammatory cytokines such as interleukin-17 (IL-17) promote inflammatory autoimmune diseases. Although several microRNAs (miRNAs) have been shown to regulate autoimmune pathogenesis by affecting lymphocyte development and function, the role of miRNAs in resident cells present in inflammatory lesions remains unclear. Here we show that miR-23b is downregulated in inflammatory lesions of humans with lupus or rheumatoid arthritis, as well as in the mouse models of lupus, rheumatoid arthritis or multiple sclerosis. IL-17 downregulates miR-23b expression in human fibroblast-like synoviocytes, mouse primary kidney cells and astrocytes and is essential for the downregulation of miR-23b during autoimmune pathogenesis. In turn, miR-23b suppresses IL-17-, tumor necrosis factor α (TNF-α)- or IL-1β-induced NF-κB activation and inflammatory cytokine expression by targeting TGF-β-activated kinase 1/MAP3K7 binding protein 2 (TAB2), TAB3 and inhibitor of nuclear factor κ-B kinase subunit α (IKK-α) and, consequently, represses autoimmune inflammation. Thus, IL-17 contributes to autoimmune pathogenesis by suppressing miR-23b expression in radio-resident cells and promoting proinflammatory cytokine expression.

Overview

Integrity signals

Registry

Crossref · 10.1038/nm.2815

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Show all 13 references

Research works printed but not linked: 45

  1. Firestein, G.S. Evolving concepts of rheumatoid arthritis. Nature 423, 356–361 (2003). · DOI
  2. Compston, A. & Coles, A. Multiple sclerosis. Lancet 372, 1502–1517 (2008). · DOI
  3. Rahman, A. & Isenberg, D.A. Systemic lupus erythematosus. N. Engl. J. Med. 358, 929–939 (2008). · DOI
  4. Zhu, S. & Qian, Y. IL-17/IL-17 receptor system in autoimmune disease: mechanisms and therapeutic potential. Clin. Sci. (Lond.) 122, 487–511 (2012). · DOI
  5. Feldmann, M., Brennan, F.M. & Maini, R.N. Role of cytokines in rheumatoid arthritis. Annu. Rev. Immunol. 14, 397–440 (1996). · DOI
  6. Smolen, J.S., Steiner, G. & Aringer, M. Anti-cytokine therapy in systemic lupus erythematosus. Lupus 14, 189–191 (2005). · DOI
  7. Williams, R.O., Paleolog, E. & Feldmann, M. Cytokine inhibitors in rheumatoid arthritis and other autoimmune diseases. Curr. Opin. Pharmacol. 7, 412–417 (2007). · DOI
  8. Hueber, W. et al. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci. Transl. Med. 2, 52ra72 (2010). · DOI · Paper page
  9. Lipsky, P.E. et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N. Engl. J. Med. 343, 1594–1602 (2000). · DOI
  10. Geyer, M. & Muller-Ladner, U. Actual status of antiinterleukin-1 therapies in rheumatic diseases. Curr. Opin. Rheumatol. 22, 246–251 (2010). · DOI
  11. Genovese, M.C. et al. LY2439821, a humanized anti–interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I randomized, double-blind, placebo-controlled, proof-of-concept study. Arthritis Rheum. 62, 929–939 (2010). · DOI
  12. Lu, L.F. et al. Function of miR-146a in controlling Treg cell–mediated regulation of Th1 responses. Cell 142, 914–929 (2010). · DOI · Paper page
  13. O'Connell, R.M. et al. MicroRNA-155 promotes autoimmune inflammation by enhancing inflammatory T cell development. Immunity 33, 607–619 (2010). · DOI · Paper page
  14. Du, C. et al. MicroRNA miR-326 regulates TH-17 differentiation and is associated with the pathogenesis of multiple sclerosis. Nat. Immunol. 10, 1252–1259 (2009). · DOI · Paper page
  15. Stittrich, A.B. et al. The microRNA miR-182 is induced by IL-2 and promotes clonal expansion of activated helper T lymphocytes. Nat. Immunol. 11, 1057–1062 (2010). · DOI
  16. Xiao, C. et al. MiR-150 controls B cell differentiation by targeting the transcription factor c-Myb. Cell 131, 146–159 (2007). · DOI
  17. Thai, T.H. et al. Regulation of the germinal center response by microRNA-155. Science 316, 604–608 (2007). · DOI
  18. Johnnidis, J.B. et al. Regulation of progenitor cell proliferation and granulocyte function by microRNA-223. Nature 451, 1125–1129 (2008). · DOI · Paper page
  19. Lu, L.F. et al. Foxp3-dependent microRNA155 confers competitive fitness to regulatory T cells by targeting SOCS1 protein. Immunity 30, 80–91 (2009). · DOI
  20. Xiao, C. et al. Lymphoproliferative disease and autoimmunity in mice with increased miR-17–92 expression in lymphocytes. Nat. Immunol. 9, 405–414 (2008). · DOI
  21. O'Connell, R.M., Rao, D.S., Chaudhuri, A.A. & Baltimore, D. Physiological and pathological roles for microRNAs in the immune system. Nat. Rev. Immunol. 10, 111–122 (2010). · DOI · Paper page
  22. Nakamachi, Y. et al. MicroRNA-124a is a key regulator of proliferation and monocyte chemoattractant protein 1 secretion in fibroblast-like synoviocytes from patients with rheumatoid arthritis. Arthritis Rheum. 60, 1294–1304 (2009). · DOI · Paper page
  23. Junker, A. et al. MicroRNA profiling of multiple sclerosis lesions identifies modulators of the regulatory protein CD47. Brain 132, 3342–3352 (2009). · DOI · Paper page
  24. Dai, Y. et al. Comprehensive analysis of microRNA expression patterns in renal biopsies of lupus nephritis patients. Rheumatol. Int. 29, 749–754 (2009). · DOI
  25. Pan, W. et al. MicroRNA-21 and microRNA-148a contribute to DNA hypomethylation in lupus CD4+ T cells by directly and indirectly targeting DNA methyltransferase 1. J. Immunol. 184, 6773–6781 (2010). · DOI
  26. Li, J. et al. Altered microRNA expression profile with miR-146a upregulation in CD4+ T cells from patients with rheumatoid arthritis. Arthritis Res. Ther. 12, R81 (2010). · DOI
  27. De Santis, G. et al. Altered miRNA expression in T regulatory cells in course of multiple sclerosis. J. Neuroimmunol. 226, 165–171 (2010). · DOI
  28. Tili, E. et al. Modulation of miR-155 and miR-125b levels following lipopolysaccharide/TNF-α stimulation and their possible roles in regulating the response to endotoxin shock. J. Immunol. 179, 5082–5089 (2007). · DOI · Paper page
  29. Sønder, S.U. et al. IL-17-induced NF-κB activation via CIKS/Act1: physiologic significance and signaling mechanisms. J. Biol. Chem. 286, 12881–12890 (2011). · DOI
  30. Ma, F. et al. The microRNA miR-29 controls innate and adaptive immune responses to intracellular bacterial infection by targeting interferon-γ. Nat. Immunol. 12, 861–869 (2011). · DOI
  31. Rodriguez, A., Griffiths-Jones, S., Ashurst, J.L. & Bradley, A. Identification of mammalian microRNA host genes and transcription units. Genome Res. 14, 1902–1910 (2004). · DOI · Paper page
  32. Yamamoto, M. et al. Regulation of Toll/IL-1-receptor-mediated gene expression by the inducible nuclear protein I(Bζ. Nature 430, 218–222 (2004). · DOI
  33. Kao, C.Y., Kim, C., Huang, F. & Wu, R. Requirements for two proximal NF-κB binding sites and IκB-ζ in IL-17A–induced human β-defensin 2 expression by conducting airway epithelium. J. Biol. Chem. 283, 15309–15318 (2008). · DOI
  34. Rossi, R.L. et al. Distinct microRNA signatures in human lymphocyte subsets and enforcement of the naive state in CD4+ T cells by the microRNA miR-125b. Nat. Immunol. 12, 796–803 (2011). · DOI
  35. Ishitani, T. et al. Role of the TAB2-related protein TAB3 in IL-1 and TNF signaling. EMBO J. 22, 6277–6288 (2003). · DOI
  36. Qian, Y., Kang, Z., Liu, C. & Li, X. IL-17 signaling in host defense and inflammatory diseases. Cell. Mol. Immunol. 7, 328–333 (2010). · DOI
  37. Onishi, R.M. & Gaffen, S.L. Interleukin-17 and its target genes: mechanisms of interleukin-17 function in disease. Immunology 129, 311–321 (2010). · DOI · Paper page
  38. Hartupee, J. et al. IL-17 signaling for mRNA stabilization does not require TNF receptor–associated factor 6. J. Immunol. 182, 1660–1666 (2009). · DOI
  39. Nakasa, T. et al. Expression of microRNA-146 in rheumatoid arthritis synovial tissue. Arthritis Rheum. 58, 1284–1292 (2008). · DOI
  40. Zhang, H. et al. Genome-wide functional screening of miR-23b as a pleiotropic modulator suppressing cancer metastasis. Nat. Commun. 2, 554 (2011). · DOI
  41. Zhu, S. et al. Modulation of experimental autoimmune encephalomyelitis through TRAF3-mediated suppression of interleukin 17 receptor signaling. J. Exp. Med. 207, 2647–2662 (2010). · DOI
  42. Kanayama, A. et al. TAB2 and TAB3 activate the NF-κB pathway through binding to polyubiquitin chains. Mol. Cell 15, 535–548 (2004). · DOI
  43. Shen, F. et al. IL-17 receptor signaling inhibits C/EBPβ by sequential phosphorylation of the regulatory 2 domain. Sci. Signal. 2, ra8 (2009). · DOI
  44. Shi, P. et al. Persistent stimulation with interleukin-17 desensitizes cells through SCFβ-TrCP–mediated degradation of Act1. Sci. Signal. 4, ra73 (2011). · DOI
  45. Austin, H.A. III., Muenz, L.R., Joyce, K.M., Antonovych, T.T. & Balow, J.E. Diffuse proliferative lupus nephritis: identification of specific pathologic features affecting renal outcome. Kidney Int. 25, 689–695 (1984). · DOI

Cited by

Sorted by citations

See all 396

Metadata

Authors
Zhu, S., Pan, W., Song, X., Liu, Y., Shao, X., Tang, Y., Liang, D., He, D., Wang, H., Liu, W., Shi, Y., Harley, J. B., Shen, N., & Qian, Y.
Venue
Nature Medicine
Publisher
Springer Science and Business Media LLC
Published
2012-06-03
Volume
18
Issue
7
Pages
1077-1086
ISSN
  • 1078-8956
  • 1546-170X
DOI
10.1038/nm.2815
Cited by
396
References
13
Language
en
Licence
www.springer.com/tdm (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review